DBV Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
DBV Technologies S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.52 |
52 Week High | €1.61 |
52 Week Low | €0.51 |
Beta | 0.38 |
1 Month Change | 96.89% |
3 Month Change | 73.49% |
1 Year Change | 27.99% |
3 Year Change | -39.13% |
5 Year Change | -87.41% |
Change since IPO | -83.10% |
Recent News & Updates
Recent updates
Revenues Not Telling The Story For DBV Technologies S.A. (EPA:DBV) After Shares Rise 76%
Jan 10DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding Up
Oct 24Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts
Aug 04Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)
Jun 14We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For Now
May 10DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50
May 09Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 10Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Dec 01Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?
Jun 23We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash Wisely
Mar 09Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation
Oct 04DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 06Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash Wisely
Mar 14Shareholder Returns
DBV | FR Biotechs | FR Market | |
---|---|---|---|
7D | 14.3% | 4.8% | 3.2% |
1Y | 28.0% | -33.0% | -7.7% |
Return vs Industry: DBV exceeded the French Biotechs industry which returned -33.4% over the past year.
Return vs Market: DBV exceeded the French Market which returned -7% over the past year.
Price Volatility
DBV volatility | |
---|---|
DBV Average Weekly Movement | 14.8% |
Biotechs Industry Average Movement | 7.2% |
Market Average Movement | 5.3% |
10% most volatile stocks in FR Market | 11.5% |
10% least volatile stocks in FR Market | 2.8% |
Stable Share Price: DBV's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: DBV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of French stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 110 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
DBV fundamental statistics | |
---|---|
Market cap | €207.48m |
Earnings (TTM) | -€100.19m |
Revenue (TTM) | €3.65m |
56.8x
P/S Ratio-2.1x
P/E RatioIs DBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DBV income statement (TTM) | |
---|---|
Revenue | US$4.15m |
Cost of Revenue | US$0 |
Gross Profit | US$4.15m |
Other Expenses | US$118.07m |
Earnings | -US$113.92m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.83 |
Gross Margin | 100.00% |
Net Profit Margin | -2,744.35% |
Debt/Equity Ratio | 0% |
How did DBV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/04/25 16:38 |
End of Day Share Price | 2025/04/25 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DBV Technologies S.A. is covered by 18 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Tazeen Ahmad | BofA Global Research |
Jean-Jacques Le Fur | Bryan Garnier & Co |
Liisa Bayko | Citizens JMP Securities, LLC |